Holen Sie sich die Stockscreener-App
14.61
2.31%
0.33
Schlusskurs vom Vortag:
$14.28
Offen:
$14.43
24-Stunden-Volumen:
54,520
Relative Volume:
0.37
Marktkapitalisierung:
$195.65M
Einnahmen:
$112.82M
Nettoeinkommen (Verlust:
$-9.98M
KGV:
-19.25
EPS:
-0.7588
Netto-Cashflow:
$4.36M
1W Leistung:
+3.54%
1M Leistung:
+33.55%
6M Leistung:
+62.33%
1J Leistung:
-5.25%
1-Tages-Spanne:
$14.40
$14.63
1-Wochen-Bereich:
$13.70
$14.62
52-Wochen-Spanne:
$7.8701
$15.79
Anika Therapeutics Inc Stock (ANIK) Company Profile
Firmenname
Anika Therapeutics Inc
Sektor
Telefon
(781) 457-9000
Adresse
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
14.60 | 191.36M | 112.82M | -9.98M | 4.36M | -0.7588 |
TAK
Takeda Pharmaceutical Co Adr
|
18.36 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.69 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.805 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.82 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
547.58 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-17 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-01 | Bestätigt | Barrington Research | Outperform |
| 2023-08-14 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | Fortgesetzt | Stephens | Equal-Weight |
| 2022-03-09 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | Eingeleitet | Stephens | Overweight |
| 2021-07-16 | Eingeleitet | UBS | Neutral |
| 2020-12-16 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | Hochstufung | Sidoti | Neutral → Buy |
| 2020-01-10 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | Eingeleitet | BWS Financial | Sell |
| 2019-09-24 | Bestätigt | Barrington Research | Outperform |
| 2019-09-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | Hochstufung | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | Herabstufung | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | Herabstufung | Sidoti | Buy → Neutral |
| 2018-07-27 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | Bestätigt | Barrington Research | Outperform |
| 2016-05-09 | Hochstufung | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | Bestätigt | Barrington Research | Outperform |
Alle ansehen
Anika Therapeutics Inc Aktie (ANIK) Neueste Nachrichten
Anika Therapeutics (NASDAQ:ANIK) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Anika Therapeutics (ANIK) SVP Ian McLeod granted RSUs and PPSARs - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
If You Invested $1,000 in Anika Therapeutics Inc (ANIK) - Stock Titan
ANIK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Regenerative Medicine Market Is Going to Boom | Anika Therapeutics, Inc. and Arthrex - openPR.com
Anika Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Anika Therapeutics (ANIK) EVP reports RSU vesting and tax share withholding - Stock Titan
Anika Therapeutics (NASDAQ: ANIK) CEO adds shares via RSU vesting and award - Stock Titan
Anika Therapeutics (ANIK) director vests RSUs, withholds shares for taxes - Stock Titan
Anika Therapeutics (NASDAQ: ANIK) SVP gains shares via RSUs, covers taxes with stock - Stock Titan
Precision Trading with Anika Therapeutics Inc. (ANIK) Risk Zones - Stock Traders Daily
Anika Therapeutics (NASDAQ:ANIK) Shares Pass Above 200-Day Moving Average – What’s Next? - Defense World
Anika Therapeutics (NASDAQ:ANIK) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
Anika Therapeutics falls after its completes divestiture of Parcus Medical business - TradingView
Anika Therapeutics (ANIK) EVP’s RSUs Vest with Shares Withheld for Taxes - Stock Titan
Anika Therapeutics (ANIK) director nets RSU shares after tax withholding - Stock Titan
Anika Therapeutics (ANIK) SVP RSUs vest; 639 shares withheld for taxes - Stock Titan
Anika signals 1%–9% revenue growth outlook for 2026 while expanding commercial channel and streamlining operations - MSN
Anika Therapeutics Earnings Call Signals Cautious Rebound - TipRanks
Jobs Data: Will Anika Therapeutics Inc. (AKP) stock gain from lower interest ratesWeekly Loss Report & Capital Efficiency Focused Ideas - Naître et grandir
Anika Therapeutics (NASDAQ:ANIK) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Bank Watch: Is Anika Therapeutics Inc still a buy after recent gains2025 AllTime Highs & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Published on: 2026-03-07 10:02:22 - baoquankhu1.vn
Trigran Investments Inc. Sells 415,296 Shares of Anika Therapeutics Inc. $ANIK - MarketBeat
Technical Reactions to ANIK Trends in Macro Strategies - Stock Traders Daily
Top 2 Health Care Stocks That May Crash This QuarterArcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK) - Benzinga
Anika Therapeutics Is Cheap, But FDA Decisions And OEM Pricing Still Rule - Finimize
Anika Therapeutics debuts Integrity and highlights portfolio at AAOS - Traders Union
Anika Therapeutics 2025 10-K: Revenue $112.8M, Diluted Loss per Share $(0.70) - TradingView
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference - Yahoo Finance
Anika Therapeutics, Inc. (ANIK) Presents at 2026 CG Musculoskeletal ConferenceSlideshow - Seeking Alpha
ANIK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Anika Therapeutics (NASDAQ: ANIK) sharpens HA strategy with asset sales - Stock Titan
Does Anika Therapeutics, Inc. (ANIK) Have Momentum? - AAII
Anika Therapeutics Q4 Earnings Call Highlights - Defense World
Anika Therapeutics (NASDAQ:ANIK) Stock Price Expected to Rise, Barrington Research Analyst Says - Defense World
Anika Therapeutics (ANIK) Receives a Buy from B. Riley Securities - The Globe and Mail
ANIK | Anika Therapeutics Inc FinancialsIncome Statement - Quiver Quantitative
Anika Therapeutics (NASDAQ:ANIK) Announces Quarterly Earnings Results - MarketBeat
Barrington Research Forecasts Strong Price Appreciation for Anika Therapeutics (NASDAQ:ANIK) Stock - MarketBeat
ANIK: Barrington Research Raises Price Target to $17, Maintains 'Outperform' | ANIK Stock News - GuruFocus
Anika Therapeutics showcases Integrity benefits at ACFAS conference - Traders Union
Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating - marketscreener.com
B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating - marketscreener.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2025 Earnings Call Transcript - Insider Monkey
Anika Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ANIK) 2026-02-27 - Seeking Alpha
Anika Therapeutics Inc (ANIK) Q4 2025 Earnings Call Highlights: - GuruFocus
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Earnings call transcript: Anika Therapeutics Q4 2025 results beat expectations - Investing.com
Anika Therapeutics (ANIK) Reports Consistent Q4 Revenue with Pro - GuruFocus
Finanzdaten der Anika Therapeutics Inc-Aktie (ANIK)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):